AVLN — Avalyn Pharma Inc. Common Stock stock price, charts and financials

QT44Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc. Common Stock (NASDAQ: AVLN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
30.73
+2.23+7.82%
OverviewShort InterestFilings
AVLNQT44Avalyn Pharma Inc. Common Stock·NASDAQ
30.73+7.82%
TA
Loading chart...
Screen all →
OCUL+2.26%$8.59MESO+2.28%$14.80AUPH+2.47%$14.93TYRA+1.53%$32.53URGN+3.45%$39.92IOVA+0.93%$4.36STOK+7.14%$31.67TSHA+7.27%$6.20
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand44.33MPerf Week10.58%
Market Cap1.36BForward P/E-EPS next Y-2.41Insider Trans-Shs Float14.45MPerf Month11.14%
Enterprise Value1.23BPEG-EPS next Q-0.58Inst Own-Short Float4.94%Perf Quarter5.71%
Income-85.00MP/S0.00EPS this Y-Inst Trans-Short Ratio4.16Perf Half Y-
Sales0.00P/B-EPS next Y12.66%ROA-57.23%Short Interest2.19MPerf YTD18.19%
Book/sh-5.39P/C9.87EPS next 5Y-ROE35.70%52W High33.32 -7.77%Perf Year-
Cash/sh3.11P/FCF-EPS past 3/5Y-ROIC-67.51%52W Low24.15 27.25%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility7.06% 6.92%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-Oper. Margin0.00%ATR (14)2.17Perf 10Y-
Dividend Ex-Date-Quick Ratio10.19Sales Y/Y TTM-Profit Margin0.00%RSI (14)57.96Recom2.00
Dividend Gr. 3/5Y-Current Ratio10.19EPS Q/Q-SMA208.14%Beta-0.10Target Price59.00
Payout0.00%Debt/Eq-Sales Q/Q-SMA506.95%Rel Volume0.49Prev Close28.50
Employees50LT Debt/Eq-0.00EarningsSep 02SMA2006.95%Avg Volume358.84KPrice30.73
IPO DateApr 30, 2026Option/ShortNo / YesEPS/Sales Surpr.-265.25% -Net Debt/EBITDA0.56Volume176,667Change7.82%
Analyst Ratings
DateActionAnalystRatingTarget
May-26-26InitiatedEvercore ISIOutperform$51
May-26-26InitiatedMorgan StanleyOverweight$53
May-25-26InitiatedJefferiesBuy$52
May-25-26InitiatedGuggenheimBuy$80
Company

Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
Total Revenue
0
Cost of Goods Sold Incl. D&A
0
Gross Profit
0
Selling, General and Administrative Excl. Other15
Research and Development77
Other Operating Expense-1
Operating Income-91
Interest Expense
0
Unusual Expense
—
Non-Operating Income (Expense)6
Net Income Before Taxes-85
Income Taxes
0
Consolidated Net Income-85
Net Income From Continuing Operations-85
Net Income-85
EPS (Recurring)-2.04
EPS (Basic, Before Extraordinaries)-2.04
EPS (Diluted)-2.04
EBITDA-91
Other After Tax Adjustments
—
Stock Option Compensation Expense
—
Price To Earnings Ratio
—
Price To Sales Ratio
—
Gross Margin
—
Operating Margin
—
Net Margin
—
Shares Outstanding42
Market Capitalization
—
Operating Lease Expense
—
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.